Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation Hemeida TS; Keane PA; Dustin L; Sadda SR; Fawzi AABr J Ophthalmol 2010[Jun]; 94 (6): 701-5AIM: To study the long-term visual and anatomical outcomes of antivascular endothelial growth factor (VEGF) monotherapy for the treatment of patients with retinal angiomatous proliferation (RAP). METHODS: Retrospective review of patients who were diagnosed as having AMD and RAP lesions, and who received anti-VEGF injections as the only mode of therapy. RESULTS: 20 eyes (15 patients; nine women, six men) with RAP lesions treated by anti-VEGF were encountered. The mean patient age was 85.8 years (SD+/-4.54). Nine eyes were treated with intravitreal ranibizumab alone, eight eyes were treated with bevacizumab alone, and three eyes received both drugs. At 1, 3 and 6 months' follow-up the median VA had improved from baseline (20/72) to 20/52 (range: 20/25 to 20/400), 20/45 (range 20/20 to 20/400), and 20/56 (range 20/20 to 20/400), respectively, (p>0.001, p=0.001 and p=0.05, respectively). At the 24-month follow-up, the improvement in VA, defined as a halving of the visual angle, occurred in 37.5% of the cases. CONCLUSIONS: Anti-VEGF monotherapy represents a useful treatment option for RAP, with stable or improved visual acuity in 62.5% of patients at 2 years. 25% of eyes required only a single injection, but in most cases (75%) repeated treatments were required, highlighting the need for long term follow-up. Although, in this small study, the results for visual improvement were not statistically significant beyond 3 months, our findings warrant further large-scale investigation.|Aged[MESH]|Aged, 80 and over[MESH]|Angiogenesis Inhibitors/*therapeutic use[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Bevacizumab[MESH]|Choroidal Neovascularization/*drug therapy/pathology/physiopathology[MESH]|Drug Evaluation/methods[MESH]|Drug Therapy, Combination[MESH]|Female[MESH]|Follow-Up Studies[MESH]|Humans[MESH]|Macular Degeneration/*drug therapy/pathology/physiopathology[MESH]|Male[MESH]|Ranibizumab[MESH]|Retrospective Studies[MESH]|Tomography, Optical Coherence[MESH]|Treatment Outcome[MESH]|Vascular Endothelial Growth Factor A/*antagonists & inhibitors[MESH]|Visual Acuity/drug effects[MESH] |